Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures.
Parkinson’s disease
biomarkers
disease progression
surrogate endpoint
Journal
Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
28
8
2019
medline:
30
7
2020
entrez:
28
8
2019
Statut:
ppublish
Résumé
Improved prediction of Parkinson's disease (PD) progression is needed to support clinical decision-making and to accelerate research trials. To examine whether baseline measures and their 1-year change predict longer-term progression in early PD. Parkinson's Progression Markers Initiative study data were used. Participants had disease duration ≤2 years, abnormal dopamine transporter (DAT) imaging, and were untreated with PD medications. Baseline and 1-year change in clinical, cerebrospinal fluid (CSF), and imaging measures were evaluated as candidate predictors of longer-term (up to 5 years) change in Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score and DAT specific binding ratios (SBR) using linear mixed-effects models. Among 413 PD participants, median follow-up was 5 years. Change in MDS-UPDRS from year-2 to last follow-up was associated with disease duration (β= 0.351; 95% CI = 0.146, 0.555), male gender (β= 3.090; 95% CI = 0.310, 5.869), and baseline (β= -0.199; 95% CI = -0.315, -0.082) and 1-year change (β= 0.540; 95% CI = 0.423, 0.658) in MDS-UPDRS; predictors in the model accounted for 17.6% of the variance in outcome. Predictors of percent change in mean SBR from year-2 to last follow-up included baseline rapid eye movement sleep behavior disorder score (β= -0.6229; 95% CI = -1.2910, 0.0452), baseline (β= 7.232; 95% CI = 2.268, 12.195) and 1-year change (β= 45.918; 95% CI = 35.994,55.843) in mean striatum SBR, and 1-year change in autonomic symptom score (β= -0.325;95% CI = -0.695, 0.045); predictors in the model accounted for 44.1% of the variance. Baseline clinical, CSF, and imaging measures in early PD predicted change in MDS-UPDRS and dopamine-transporter binding, but the predictive value of the models was low. Adding the short-term change of possible predictors improved the predictive value, especially for modeling change in dopamine-transporter binding.
Sections du résumé
BACKGROUND
Improved prediction of Parkinson's disease (PD) progression is needed to support clinical decision-making and to accelerate research trials.
OBJECTIVES
To examine whether baseline measures and their 1-year change predict longer-term progression in early PD.
METHODS
Parkinson's Progression Markers Initiative study data were used. Participants had disease duration ≤2 years, abnormal dopamine transporter (DAT) imaging, and were untreated with PD medications. Baseline and 1-year change in clinical, cerebrospinal fluid (CSF), and imaging measures were evaluated as candidate predictors of longer-term (up to 5 years) change in Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score and DAT specific binding ratios (SBR) using linear mixed-effects models.
RESULTS
Among 413 PD participants, median follow-up was 5 years. Change in MDS-UPDRS from year-2 to last follow-up was associated with disease duration (β= 0.351; 95% CI = 0.146, 0.555), male gender (β= 3.090; 95% CI = 0.310, 5.869), and baseline (β= -0.199; 95% CI = -0.315, -0.082) and 1-year change (β= 0.540; 95% CI = 0.423, 0.658) in MDS-UPDRS; predictors in the model accounted for 17.6% of the variance in outcome. Predictors of percent change in mean SBR from year-2 to last follow-up included baseline rapid eye movement sleep behavior disorder score (β= -0.6229; 95% CI = -1.2910, 0.0452), baseline (β= 7.232; 95% CI = 2.268, 12.195) and 1-year change (β= 45.918; 95% CI = 35.994,55.843) in mean striatum SBR, and 1-year change in autonomic symptom score (β= -0.325;95% CI = -0.695, 0.045); predictors in the model accounted for 44.1% of the variance.
CONCLUSIONS
Baseline clinical, CSF, and imaging measures in early PD predicted change in MDS-UPDRS and dopamine-transporter binding, but the predictive value of the models was low. Adding the short-term change of possible predictors improved the predictive value, especially for modeling change in dopamine-transporter binding.
Identifiants
pubmed: 31450510
pii: JPD181518
doi: 10.3233/JPD-181518
pmc: PMC6839498
doi:
Substances chimiques
Biomarkers
0
Dopamine Plasma Membrane Transport Proteins
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
665-679Références
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):610-7
pubmed: 25286015
Lancet Neurol. 2017 Nov;16(11):908-916
pubmed: 28958801
Mov Disord. 2007 Oct 15;22(13):1839-51; quiz 1988
pubmed: 17595026
Acta Neurol Scand. 2014 Mar;129(3):204-8
pubmed: 23962145
Acta Neurol Scand. 2017 Apr;135(4):400-406
pubmed: 27255673
JAMA Neurol. 2013 Oct;70(10):1277-87
pubmed: 23979011
Parkinsonism Relat Disord. 2016 Jul;28:62-7
pubmed: 27132498
Mov Disord. 2016 Jul;31(7):947-956
pubmed: 27226141
Sci Rep. 2016 Jun 01;6:26782
pubmed: 27245317
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
Am J Geriatr Psychiatry. 2006 Feb;14(2):169-75
pubmed: 16473982
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Stat Med. 1985 Jan-Mar;4(1):39-46
pubmed: 3857702
Ann Clin Transl Neurol. 2016 May 17;3(7):482-94
pubmed: 27386498
Eur J Neurol. 2015 Mar;22(3):457-63
pubmed: 24888502
Front Psychol. 2012 Apr 17;3:111
pubmed: 22529829
Neurology. 2018 Mar 20;90(12):e1038-e1046
pubmed: 29467305
Mov Disord. 2004 Nov;19(11):1306-12
pubmed: 15390007
Brain. 2017 Jul 1;140(7):1959-1976
pubmed: 28549077
Prog Neurobiol. 2011 Dec;95(4):629-35
pubmed: 21930184
Mov Disord. 2015 Sep;30(10):1413-7
pubmed: 26265105
Stat Med. 1989 Jul;8(7):771-83
pubmed: 2672226
Mov Disord. 2018 May;33(5):771-782
pubmed: 29572948
Clin Transl Sci. 2018 Jan;11(1):63-70
pubmed: 28749580
Mov Disord. 2013 May;28(5):668-70
pubmed: 23408503